Decapeptide-12 Topical (200mg)

Decapeptide-12 Topical (200mg) is a lyophilized research peptide synthesized, purified, and lyophilized in the USA. Each production batch is purified by repeated rounds of reverse-phase HPLC and identity-confirmed by mass spectrometry.

Researchers using Decapeptide-12 Topical (200mg) validate peptide stability in topical vehicle systems before experimental application.

Decapeptide-12 Topical (200mg) is often screened alongside other matrix peptides to compare activity profiles in vitro.

Laboratory work on Decapeptide-12 Topical (200mg) emphasizes controlled concentration studies and reproducible assay conditions.

Each vial contains lyophilized peptide at the labeled quantity, and wholesale orders are packed in boxes of ten vials at a single per-vial price.

Quality assurance: every batch is purified by reversed-phase high-performance liquid chromatography and identity-confirmed by mass spectrometry, with purity above 99%. Lot-specific certificates of analysis are available on request. Store lyophilized vials at -20°C, protected from light and moisture; reconstitute with bacteriostatic water immediately before use and avoid repeated freeze-thaw cycles. For in-vitro laboratory research use only —not for human or veterinary use.

Research & Literature

The following peer-reviewed studies and reference documents are commonly consulted by researchers working with Decapeptide-12 Topical (200mg). Summaries are provided for orientation only and reflect the cited sources.

Enhanced skin retention and permeation of a novel peptide via structural modification, chemical enhancement, and microneedles^[1] —This study characterized decapeptide-12 as a peptide with melanin-reducing activity that may offer a safer alternative to hydroquinone for skin brightening. The authors explored strategies to improve its cutaneous delivery, including structural modification via palmitoylation, chemical penetration enhancers, and microneedle-assisted application. Their results indicated that these approaches could enhance skin retention and permeation of the peptide, supporting its potential use in topical brightening products. (International Journal of Pharmaceutics 2021)

Combined topical delivery and dermalinfusion of decapeptide-12 accelerates resolution of post-inflammatory hyperpigmentation in skin of color^[2] —This case series examined the effects of topical decapeptide-12, used alone or combined with dermalinfusion, in patients with post-inflammatory hyperpigmentation in skin of color. The authors reported accelerated resolution of hyperpigmentation in the treated cases. The findings suggested that decapeptide-12-based protocols may be a well-tolerated option for managing this pigmentary concern. (Journal of Drugs in Dermatology 2014)

Open-label evaluation of a novel skin brightening system containing 0.01% decapeptide-12 in combination with 20% buffered glycolic acid for the treatment of mild to moderate facial melasma^[3] —This open-label study evaluated a skin brightening system containing 0.01% decapeptide-12 combined with 20% buffered glycolic acid in subjects with mild to moderate facial melasma. The authors assessed changes in pigmentation and overall skin appearance. They reported improvement in melasma severity, suggesting that the combination may provide a benefit for this condition. (Journal of Drugs in Dermatology 2013)

References

1. Chen J, Bian J, Hantash BM, Albakr L, Hibbs DE, Xiang X, Xie P, Wu C, Kang L. "Enhanced skin retention and permeation of a novel peptide via structural modification, chemical enhancement, and microneedles." International Journal of Pharmaceutics. 2021. pubmed.ncbi.nlm.nih.gov/34242628/
2. Bhatia A, Hsu JTs, Hantash BM. "Combined topical delivery and dermalinfusion of decapeptide-12 accelerates resolution of post-inflammatory hyperpigmentation in skin of color." Journal of Drugs in Dermatology. 2014. pubmed.ncbi.nlm.nih.gov/24385124/
3. Ramírez SP, Carvajal AC, Salazar JC, Arroyave G, Flórez AM, Echeverry HF. "Open-label evaluation of a novel skin brightening system containing 0.01% decapeptide-12 in combination with 20% buffered glycolic acid for the treatment of mild to moderate facial melasma." Journal of Drugs in Dermatology. 2013. pubmed.ncbi.nlm.nih.gov/23839199/

All products are supplied as lyophilized powder for in-vitro laboratory research use only and are not for human or veterinary use.